STIFEL FINANCIAL CORP

Position in RXRX — Recursion Pharmaceuticals, Inc.

CIK 720672 ST. LOUIS, MO

Position in RXRX

as of Jun 30, 2026 · filed Aug 12, 2026 Compact

Position Value

$3,234,946

+$849,779 QoQ

Shares Held

881,457

+13.5% QoQ

Ownership

0.165%

of shares outstanding

% of Portfolio

0.00%

of 13F equity value

Holder Rank

#36

of 344 holders

Holding Since

Dec 2023

11 quarters on record

Voting authority Sole 98% Shared 0% None 2%

Healthcare · as of Jun 30, 2026

STIFEL FINANCIAL CORP holds $538,947,950 across 105 Biotechnology names. RXRX ranks #22 (0.6% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	BHVN	Biohaven Ltd.	9,941,165	$147,924,534
2	VRTX	Vertex Pharmaceuticals Inc / Ma	162,151	$80,545,262
3	MANE	Veradermics, Inc	294,117	$36,158,743
4	JAZZ	Jazz Pharmaceuticals plc	139,491	$33,613,146
5	REGN	Regeneron Pharmaceuticals, Inc.	46,378	$28,918,535
6	OMER	Omeros Corp	1,836,925	$17,469,155
7	NTLA	Intellia Therapeutics, Inc.	1,014,387	$17,163,427
8	IONS	Ionis Pharmaceuticals Inc	202,983	$16,094,521

11 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$3,234,946	881,457	+13.5%	Shares	Defined	2026-08-12
2026-03-31	$2,385,167	776,928	+31.6%	Shares	Defined	2026-05-12
2025-12-31	$2,413,704	590,148	+33.3%	Shares	Defined	2026-02-13
2025-09-30	$2,160,839	442,795	+72.9%	Shares	Defined	2025-11-12
2025-06-30	$1,295,825	256,092	+36.8%	Shares	Defined	2025-08-14
2025-03-31	$990,599	187,259	+17.1%	Shares	Defined	2025-05-14
2024-12-31	$1,080,834	159,887	-1.3%	Shares	Defined	2025-02-13
2024-09-30	$1,067,434	161,978	+48.8%	Shares	Defined	2024-11-14
2024-06-30	$816,561	108,875	+145.2%	Shares	Defined	2024-08-13
2024-03-31	$442,756	44,409	+63.3%	Shares	Defined	2024-05-14
2023-12-31	$268,083	27,189	—	Shares	Defined	2024-02-12
No filing history on record for this holder in this stock.